NASDAQ:AMEDAmedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMED shares have increased by 39.0% and is now trading at $236.97.
View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings data on Tuesday, July, 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.81 by $0.53. The health services provider had revenue of $485.06 million for the quarter, compared to analyst estimates of $468.38 million. Amedisys had a return on equity of 22.41% and a net margin of 6.50%. Amedisys's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the company earned $1.21 earnings per share.
View Amedisys' earnings history.

Amedisys updated its FY20 earnings guidance on Tuesday, July, 28th. The company provided earnings per share (EPS) guidance of $4.84-5.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.54. The company issued revenue guidance of $2.04-2.07 billion, compared to the consensus revenue estimate of $2.03 billion.

13 Wall Street analysts have issued 1-year price objectives for Amedisys' shares. Their forecasts range from $160.00 to $270.00. On average, they expect Amedisys' stock price to reach $224.38 in the next twelve months. This suggests that the stock has a possible downside of 5.3%.
View analysts' price targets for Amedisys.

Media stories about AMED stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news impact score of 2.1 on InfoTrie's scale. They also gave news headlines about the health services provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Amedisys.

Amedisys saw a drop in short interest in July. As of July 31st, there was short interest totaling 926,200 shares, a drop of 24.1% from the July 15th total of 1,220,000 shares. Based on an average daily volume of 382,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 2.9% of the shares of the company are sold short.
View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.08%), Principal Financial Group Inc. (0.38%), Great Lakes Advisors LLC (0.28%), Retirement Systems of Alabama (0.27%), Russell Investments Group Ltd. (0.23%) and Swiss National Bank (0.22%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps.
View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Russell Investments Group Ltd., Columbus Circle Investors, Calamos Advisors LLC, Great Lakes Advisors LLC, SG Americas Securities LLC, First Trust Advisors LP, and Hancock Whitney Corp. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David L Kemmerly, Denise M Bohnert, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz.
View insider buying and selling activity for Amedisys.

AMED stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Principal Financial Group Inc., New York State Common Retirement Fund, Riverbridge Partners LLC, Swiss National Bank, Essex Investment Management Co. LLC, Empowered Funds LLC, and Polianta Ltd. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps.
View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $236.97.

Amedisys has a market capitalization of $7.69 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]